BeiGene Presents Clinical Data On Sitravatinib In Combination With Tislelizumab At The AACR Annual Meeting 2021 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical data on its anti-PD-1 antibody tislelizumab, in combination with the investigational spectrum-selective kinase inhibitor sitravatinib being jointly developed with Mirati Therapeutics, Inc.
Lyra Therapeutics Presents Positive Full Data Set From LANTERN Phase 2 Study Of LYR-210 At COSM 2021 Virtual Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today presented data from its Phase 2
Red Handed? Company Warns of Continued Benzene Risk in Hand Sanitizers Startup pharmacy Valisure made headlines last month for warning of a carcinogen contamination in several products from China and elsewhere. The FDA has yet to act. Late last month, a pharmacy startup made headlines for its study that found a dangerous, cancer-causing chemical compound in hand sanitizers. But have